Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis

Matrix Biology

Volumn 32, Issue 2, 2013, Pages 123-132

  Lindner, Daniel J ^a   Wu, Yan ^a   Haney, Rebecca ^a   Jacobs, Barbara S ^a   Fruehauf, John P ^b   Tuthill, Ralph ^a   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 Aza deoxycytidine; Anti angiogenesis; Methyltransferase inhibitor; Promoter hypermethylation; Thrombospondin 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; METHYLATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; AZACITIDINE; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; METHYLATION; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 84875808286     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2012.11.010     Document Type: Article

References (54)

1. Alleman W.G., Tabios R.L., Chandramouli G.V., Aprelikova O.N., Torres-Cabala C., Mendoza A., Rogers C., Sopko N.A., Linehan W.M., Vasselli J.R. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. Clin. Cancer Res. 2004, 10:7011-7021.
2. Al-Romaih K., Somers G.R., Bayani J., Hughes S., Prasad M., Cutz J.C., Xue H., Zielenska M., Wang Y., Squire J.A. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int. 2007, 7:14.
3. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
4. Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12917-12922.
5. Cantor J.P., Iliopoulos D., Rao A.S., Druck T., Semba S., Han S.Y., McCorkell K.A., Lakshman T.V., Collins J.E., Wachsberger P., Friedberg J.S., Huebner K. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int. J. Cancer 2007, 120:24-31.
6. Eramo A., Pallini R., Lotti F., Sette G., Patti M., Bartucci M., Ricci-Vitiani L., Signore M., Stassi G., Larocca L.M., Crino L., Peschle C., De Maria R. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res. 2005, 65:11469-11477.
7. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
8. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., Jacob S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 2005, 25:4727-4741.
9. Guo Z.S., Hong J.A., Irvine K.R., Chen G.A., Spiess P.J., Liu Y., Zeng G., Wunderlich J.R., Nguyen D.M., Restifo N.P., Schrump D.S. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006, 66:1105-1113.
10. Hellebrekers D.M., Jair K.W., Vire E., Eguchi S., Hoebers N.T., Fraga M.F., Esteller M., Fuks F., Baylin S.B., van Engeland M., Griffioen A.W. Angiostatic activity of DNA methyltransferase inhibitors. Mol. Cancer Ther. 2006, 5:467-475.
11. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
12. Hoon D.S., Spugnardi M., Kuo C., Huang S.K., Morton D.L., Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004, 23:4014-4022.
13. Jain R.K. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer 2008, 8:309-316.
14. Janson P.C., Marits P., Thorn M., Ohlsson R., Winqvist O. CpG methylation of the IFNG gene as a mechanism to induce immunosuppression [correction of immunosupression] in tumor-infiltrating lymphocytes. J. Immunol. 2008, 181:2878-2886.
15. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
16. Jung Y., Park J., Kim T.Y., Park J.H., Jong H.S., Im S.A., Robertson K.D., Bang Y.J., Kim T.Y. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J. Mol. Med. 2007, 85:1137-1148.
17. Kaminski R., Kozar K., Niderla J., Grzela T., Wilczynski G., Skierski J.S., Koronkiewicz M., Jakobisiak M., Golab J. Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncol. Rep. 2004, 12:509-516.
18. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
19. Kim H.C., Kim J.C., Roh S.A., Yu C.S., Yook J.H., Oh S.T., Kim B.S., Park K.C., Chang R. Aberrant CpG island methylation in early-onset sporadic gastric carcinoma. J. Cancer Res. Clin. Oncol. 2005, 131:733-740.
20. Kozar K., Kaminski R., Switaj T., Oldak T., Machaj E., Wysocki P.J., Mackiewicz A., Lasek W., Jakobisiak M., Golab J. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin. Cancer Res. 2003, 9:3124-3133.
21. Laird P.W., Jackson-Grusby L., Fazeli A., Dickinson S.L., Jung W.E., Li E., Weinberg R.A., Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995, 81:197-205.
22. Lee S., Hwang K.S., Lee H.J., Kim J.S., Kang G.H. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab. Invest. 2004, 84:884-893.
23. Leone A., Flatow U., VanHoutte K., Steeg P.S. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 1993, 8:2325-2333.
24. Li Q., Ahuja N., Burger P.C., Issa J.P. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 1999, 18:3284-3289.
25. Liang G., Gonzales F.A., Jones P.A., Orntoft T.F., Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62:961-966.
26. Manning J., Indrova M., Lubyova B., Pribylova H., Bieblova J., Hejnar J., Simova J., Jandlova T., Bubenik J., Reinis M. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 2008, 123:218-227.
27. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin. Oncol. 2005, 32:443-451.
28. Natsume A., Wakabayashi T., Tsujimura K., Shimato S., Ito M., Kuzushima K., Kondo Y., Sekido Y., Kawatsura H., Narita Y., Yoshida J. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int. J. Cancer 2008, 122:2542-2553.
29. Naumov G.N., Akslen L.A., Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006, 5:1779-1787.
30. Naumov G.N., Bender E., Zurakowski D., Kang S.Y., Sampson D., Flynn E., Watnick R.S., Straume O., Akslen L.A., Folkman J., Almog N. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl. Cancer Inst. 2006, 98:316-325.
31. Pratt D.A., Miller W.R., Dawes J. Thrombospondin in malignant and non-malignant breast tissue. Eur. J. Cancer Clin. Oncol. 1989, 25:343-350.
32. Rastinejad F., Polverini P.J., Bouck N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989, 56:345-355.
33. Reid T.R., Merigan T.C., Basham T.Y. Resistance to interferon-alpha in a mouse B-cell lymphoma involves DNA methylation. J. Interferon Res. 1992, 12:131-137.
34. Reu F.J., Bae S.I., Cherkassky L., Leaman D.W., Lindner D., Beaulieu N., Macleod A.R., Borden E.C. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J. Clin. Oncol. 2006, 24:3771-3779.
35. Reu F.J., Leaman D.W., Maitra R.R., Bae S.I., Cherkassky L., Fox M.W., Rempinski D.R., Beaulieu N., MacLeod A.R., Borden E.C. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res. 2006, 66:2785-2793.
36. Robert M.F., Morin S., Beaulieu N., Gauthier F., Chute I.C., Barsalou A., MacLeod A.R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 2003, 33:61-65.
37. Rofstad E.K., Graff B.A. Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts. J. Invest. Dermatol. 2001, 117:1042-1049.
38. Rojas A., Meherem S., Kim Y.H., Washington M.K., Willis J.E., Markowitz S.D., Grady W.M. The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int. J. Cancer 2008, 123:14-21.
39. Saudemont A., Hamrouni A., Marchetti P., Liu J., Jouy N., Hetuin D., Colucci F., Quesnel B. Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res. 2007, 67:4491-4498.
40. Sidky Y.A., Auerbach R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 1976, 192:1237-1238.
41. Sidky Y.A., Borden E.C., Wierenga W., Bryan G.T. Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. Cancer Res. 1986, 46:3798-3802.
42. Sigalotti L., Coral S., Fratta E., Lamaj E., Danielli R., Di Giacomo A.M., Altomonte M., Maio M. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin. Oncol. 2005, 32:473-478.
43. Silverstein R.L., Febbraio M. CD36-TSP-HRGP interactions in the regulation of angiogenesis. Curr. Pharm. Des. 2007, 13:3559-3567.
44. Spugnardi M., Tommasi S., Dammann R., Pfeifer G.P., Hoon D.S. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 2003, 63:1639-1643.
45. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P., Herman J.G., Baylin S.B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 2002, 31:141-149.
46. Tang Q.B., Sun H.W., Zou S.Q. Inhibitory effect of methylation inhibitor 5-aza-2-deoxycytidine on bile duct cancer cell line in vivo and in vitro. Hepatobiliary Pancreat. Dis. Int. 2004, 3:124-128.
47. Taylor K.L., Oates R.K., Grane R.W., Leaman D.W., Borden E.C., Lindner D.J. Interferon-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J. Interferon Cytokine Res. 2006, 26:353-361.
48. Trapp V., Parmakhtiar B., Papazian V., Willmott L., Fruehauf J.P. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 2010, 13:305-315.
49. Venturelli S., Armeanu S., Pathil A., Hsieh C.J., Weiss T.S., Vonthein R., Wehrmann M., Gregor M., Lauer U.M., Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007, 109:2132-2141.
50. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84:1875-1887.
51. Yang Q.W., Liu S., Tian Y., Salwen H.R., Chlenski A., Weinstein J., Cohn S.L. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003, 63:6299-6310.
52. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
53. Zabrenetzky V., Harris C.C., Steeg P.S., Roberts D.D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 1994, 59:191-195.
54. Zorn C.S., Wojno K.J., McCabe M.T., Kuefer R., Gschwend J.E., Day M.L. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin. Cancer Res. 2007, 13:2136-2143.